Announcements Trials
Browse Landscape

Phase

Phase NA 1

Status

Unknown 1

Sponsor Class

OTHER 21INDUSTRY 5OTHER_GOV 1

Study Type

Interventional 1

Sponsor

Cancer Type

CNS 1

Conditions

Meningeal Carcinomatosis 1Brain Neoplasms 1

Interventions

apatinib 25Cisplatin 19Capecitabine 17Irinotecan 16Cyclophosphamide 16fludarabine 14Radiotherapy 12Oxaliplatin 12Drug Therapy 12camrelizumab 11Paclitaxel 11S 1 (combination) 10Docetaxel 10Carboplatin 10Fluorouracil 9Blood Specimen Collection 9Bevacizumab 9Nivolumab 8tislelizumab 7Radiation 7Pemetrexed 7Gemcitabine 7Erlotinib Hydrochloride 7Surgical Procedures, Operative 6Neoadjuvant Therapy 6Albumin-Bound Paclitaxel 6toripalimab 5anlotinib 5XELOX 5Tamoxifen 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Unknown × OTHER_GOV × aumolertinib × Clear all
NCT04778800 2021-08-31

A Dose Exploration Study of Almonertinib for EGFRm NSCLC Patients With Brain/Leptomeningeal Metastasis (ARTISTRY)

Henan Cancer Hospital

Phase NA Unknown
60 enrolled
CNS

Brain Neoplasms, Meningeal Carcinomatosis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡